Sharing-our-perspective-page-header2



Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward



FDA approves new device for opioid withdrawal symptoms

by | Jul 03, 2018

DyAnsys Inc. announced that the U.S. Food and Drug Administration (FDA) approved its non-opioid, percutaneous electrical nerve field stimulator device, Drug Relief®, for use as an aid to reduce opioid withdrawal symptoms. This device sends electrical pulses through tiny needles strategically positioned in the ear to relieve symptoms during the early stages of withdrawal, including but not limited to, agitation, anxiety, depression, nausea, and cravings, and to increase the level of comfort and mobility for the claimant. 

It has been reported that this device may provide relief of symptoms within 30 to 60 minutes of starting treatment and can be used continuously for over five days, or 120 hours. 

Drug Relief® is now available to providers to prescribe during opioid detoxification as part of a comprehensive rehabilitation program.   

For more information on this product, please click here.


Sources:
  1. P&T Community. FDA Clears Wearable Device to Treat Opioid Addiction. June 12, 2018. Available at: https://www.ptcommunity.com/news/20180612/fda-clears-wearable-device-treat-opioid-addiction
    Accessed July 2, 2018
  2. DyAnsys Inc. Products and Applications. Drug Relief®. Available at: https://www.dyansys.com/products-applications/products/drug-relief   Accessed July 2, 2018.


Questions for our
Government Affairs team? 







Subscribe

Stay informed by signing up to receive our latest updates.